Subcutaneous allergen immunotherapy has been extensively used for venom allergy and some respiratory allergies. However, its use in food allergy has not been pursued because of the high risk of anaphylactic shock. 3 Allergen immunotherapy delivered by the oral route (oral immunotherapy [OIT] ) has been the focus of several recent trials. 4, 5 It was thought that the oral route, in addition to being safer than subcutaneous immunotherapy, would facilitate sustained immune tolerance because of the regulatory tone of the mucosal immune system. Although OIT successfully induces a desensitized state, defined as protection while on therapy, permanent tolerance induction after OIT has been more elusive. 4, [6] [7] [8] Oral tolerance is a state of systemic unresponsiveness induced by antigens delivered by the oral route. It is an active process mediated by antigen-specific regulatory T (Treg) cells. 9, 10 The therapeutic potential of oral tolerance has been studied for multiple sclerosis, 11 arthritis, 12 diabetes, 13 and colitis. 14 The translation of oral tolerance from prevention to treatment strategy has been limited, suggesting that previous immunity may impair the development of regulatory responses. This is consistent with the lack of sustained tolerance in response to OIT in human trials 4, 6, 8 and in mouse models of OIT. 15, 16 We hypothesized that an altered gastrointestinal immune milieu in food allergy was preventing the generation of Treg cells, and that provision of antigen by an alternative route could bypass this defective regulatory response. The skin is a highly active immune site capable of generating tolerance or immunity. We investigated the epicutaneous route through the use of Viaskin patches, which have been shown to suppress inflammation in experimental models of asthma and eosinophilic esophagitis through the generation of Treg cells. [17] [18] [19] [20] [21] We show for the first time that the epicutaneous route of antigen delivery protected mice from food-induced anaphylaxis and supported the selective expansion of a population of unique gut-homing latency-associated peptide (LAP) 1 Treg cells. These Treg cells did not function by suppressing IgE antibodies, but instead directly suppressed mast cell activation, leading to sustained clinical protection against food-induced anaphylaxis. These data show that the unique immune communication between skin and gastrointestinal tract can be used to generate long-term tolerance in food allergy.
METHODS Mice
C3H/HeJ and Balb/c mice were obtained from Jackson Laboratories (Bar Harbor, Me) and NCI (Frederick, Md), respectively. DO11.10 mice (Jackson Laboratories) were maintained as breeding colonies at Mount Sinai. All procedures were approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee.
Sensitization of mice
Mice were sensitized once a week for 6 weeks with ovalbumin (OVA, grade V; Sigma, St Louis, Mo) or peanut by epicutaneous or oral exposure. For skin sensitization, abdominal fur was removed with depilatory cream (Veet; Reckitt Benckiser, Parsippany, NJ), immediately followed by application of 100 mg OVA or 1 mg of peanut extract in 50 mL of PBS spread on the skin to dry. Epicutaneous sensitization was performed in the absence of adjuvant or tape stripping. Mice were orally sensitized with 1 mg of OVA or 10 mg of ground peanut 1 10 mg of cholera toxin (CT) (List Biologicals, Campbell, Calif) by gavage. Mice were passively sensitized by injection with 100 mL of pooled serum from actively sensitized mice. Oral challenge was performed as previously described. 15 For additional information, see the Online Repository at www.jacionline.org.
Immunotherapy treatment
After sensitization, mice received epicutaneous immunotherapy (EPIT) or OIT. EPIT was performed using EDS Viaskin patches (DBV Technologies, Paris, France) loaded with 100 mg OVA, as previously described. 18 Briefly, mice were anesthetized, the back shaved with an electric clipper, depilatory cream applied, and 24 hours later the patch was placed on the back for 48 hours. This was repeated once per week for 8 weeks. OIT was performed by the administration of 1 mg of OVA per day, in drinking water, daily, for 8 weeks.
Adoptive cell-transfer experiments

CD4
1 T cells from DO11.10 mice were purified by negative selection 
TGF-b blockade
EPIT-treated mice were injected intraperitoneally with neutralizing anti-TFG-b (1D11) (1 mg) or isotype control (both from BioXCell, West Lebanon, NH) 24 hours before challenge.
In vivo Treg-cell transfer
CD25
2 T cells were sorted from DO11.10 mice and transferred (10 5 cells/mouse) into passively sensitized Balb/c mice. After 24 hours, recipient mice were orally challenged with OVA. Symptoms were monitored and blood samples were obtained 30 minutes after challenge. In some experiments, 1 mg of anti-TGF-b antibody was injected at the same time as the cells.
Serum MCPT-7 ELISA
For detection of MCPT-7, serum was incubated on plates covered with antimTryptase b-1/MCPT7 (R&D Systems, Minneapolis, Minn), followed by detection with biotinylated anti-mTryptase b-1 (R&D Systems), horseradish peroxidase-labeled avidin (eBioscience, San Diego, Calif), and TMB substrate (eBioscience).
Statistics
Differences between groups were analyzed by Mann-Whitney U test, AN-OVA, or Kruskal-Wallis test followed by post hoc analysis with Dunn, Sidak, or Tukey multiple comparisons test or by multiple t test with Sidak-Bonferroni method for correction of multiple comparisons when appropriate. Data analysis was done by using Prism software (GraphPad, San Diego, Calif). Results are expressed as mean 6 SEM. A value of P less than .05 was considered significant.
RESULTS
EPIT induces sustained clinical protection in a model of food-induced anaphylaxis
A lack of permanent tolerance to foods after OIT has been described in both mouse and human studies. We studied the outcome of EPIT and OIT in a model of oral OVA-induced anaphylaxis. To determine whether the route of primary sensitization was a factor in the outcome of immunotherapy, we used mice that had been sensitized to OVA through either epicutaneous or oral route, followed by 8 weeks of EPIT or OIT (Fig 1, A) . At the end of the treatment, mice were orally challenged with OVA and anaphylaxis measured by drop in body temperature. Mice sensitized by the epicutaneous route developed anaphylaxis on oral challenge with OVA, whereas mice subjected to EPIT or OIT were completely protected (Fig 1, B) . When mice were challenged again to test sustained protection after 4 weeks without treatment, mice treated with EPIT were still significantly protected against anaphylaxis whereas mice treated with OIT regained clinical reactivity. However, there was no statistical difference between OIT-and EPIT-treated groups at the 12-week time point. In mice orally sensitized to OVA using CT adjuvant, mice treated with EPIT were completely protected from anaphylaxis (Fig 1, C) but mice treated with OIT were not protected. However, 4 weeks later, even EPIT-treated mice lost protection against anaphylaxis (Fig 1, C) . We hypothesized that this difference in outcome between mice sensitized by the oral route or the epicutaneous route could be due to exogenous adjuvant (CT) needed during oral sensitization. To test that, mice were sensitized by the epicutaneous route using CT adjuvant and then subjected to EPIT. Similar to the response to EPIT in orally sensitized mice, mice sensitized by the epicutaneous route with exogenous adjuvant were protected from anaphylaxis while on EPIT but not after termination of EPIT (see Fig E1 in this article's Online Repository at www.jacionline.org). Our results show that independent of the primary route of sensitization, EPIT led to a robust clinical protection against food-induced anaphylaxis.
Blood samples were taken to quantify specific immunoglobulins and basophil activation. There was a significant increase in OVAspecific IgG 1 and IgG 2a levels after 8 weeks of EPIT (Fig 2, A) , which persisted in skin-sensitized mice at week 12. IgE levels B, Oral challenge with OVA in skin-sensitized mice at weeks 8 and 12. Body temperature 30 minutes after challenge is shown. C, Oral challenge with OVA in orally sensitized mice at weeks 8 and 12. Data are individual mice from 2 independent experiments. x 5 death. *P < .05, **P < .01, and ***P < .001. also increased during the treatment but remained stable after 12 weeks. Despite these changes in immunoglobulin levels, functional assays did not support a role for antibodies in clinical protection after EPIT. Basophil activation tests showed no significant difference between untreated and EPIT-treated mice (Fig 2, B) . Second, passive sensitization of naive mice with sera from untreated or EPIT-treated mice generated similar degrees of anaphylaxis after recipient mice were orally challenged (Fig 2, C) . These results suggest that although EPIT modified the humoral response to OVA, the protection against anaphylaxis was likely mediated by a mechanism other than blocking antibodies.
Expansion of Treg cells by oral antigen is impaired in allergic mice
We hypothesized that the altered gut immune environment in food allergy is poorly tolerogenic and the lack of maintained clinical tolerance after OIT is related to defect in Treg-cell generation in the gut when antigen is applied orally. To study the response to immunotherapy of antigen-specific Treg cells in the gastrointestinal tract of allergic mice, we used an adoptive transfer model. CFSE-labeled CD41 T cells from DO11.10 transgenic mice (recognizing the 323-339 epitope of the egg allergen OVA) were transferred to naive or OVA-sensitized recipient mice before repeated low-dose feeding with OVA ( Fig  3, A) . We quantified the expansion of Foxp3 1 cells and LAP 1 cells within proliferating cells (Fig 3, B) . After 5 days of oral antigen, there was an expansion of both Foxp3 1 and LAP 1 antigenspecific Treg-cell populations in MLN of naive mice (Fig 3, C) , consistent with induction of a tolerance response. LAP 1 T cells in the proliferating compartment did not express CD25, whereas nontransgenic LAP 1 T cells found within the MLN were found to be either negative or positive for CD25. We confirmed in suppression assays that LAP 1 T cells had regulatory activity similar to that of LAP 2
CD25
1 Treg cells independent of the expression of CD25 (see Fig E2 in this article's Online Repository at www. jacionline.org). The expansion of Treg cells after oral antigen was observed in MLN but not in distal sites such as spleen (Fig  3, D) . In contrast, in mice that were OVA-sensitized before Tcell transfer and OVA feeding, the expansion of Foxp3 1 and LAP 1 Treg cells was completely abrogated (Fig 3, C) . The defect in Treg-cell generation after oral antigen feeding was observed in mice sensitized by either the oral route or the epicutaneous route and therefore is a feature of the allergic state. When mice were sensitized to a bystander antigen (peanut), the generation of OVA-specific Treg cells was not impaired, demonstrating the antigen specificity of this Treg-cell defect (Fig 3, E) .
EPIT expands LAP 1 Treg cells in the gastrointestinal tract of allergic mice
On the basis of results of the anaphylaxis model, we hypothesized that antigen delivered via the skin could induce Treg cells in sensitized mice. We first examined the induction of antigenspecific Treg cells in the skin-draining lymph nodes. There was an increase in proliferating LAP 1 but not Foxp3 1 Treg cells in comparison with untreated mice in brachial lymph nodes 1 week after applying antigen (Fig 4, B) . As with oral exposure, there was no selective expansion of Treg cells in the spleen after epicutaneous OVA. Unexpectedly, there was a significant expansion of LAP 1 Treg cells in the MLN of mice after epicutaneous OVA (Fig 4,  B) . Furthermore, this expansion of LAP 1 Treg cells in the MLN was not impaired in mice sensitized by either the oral route or the skin route (Fig 4, C) . There was also an increased frequency of DO11.10 cells in the small intestinal lamina propria after epicutaneous OVA, which were highly enriched in LAP 1 Treg cells (Fig 4, D) . This was selective to the gastrointestinal tissues, as other nondraining lymph nodes (inguinal lymph nodes) demonstrated no expansion of LAP 1 Treg cells (data not shown). These data demonstrate that epicutaneous antigen exposure can result in the appearance of Treg cells in the gastrointestinal tract, and this is observed in naive mice and also allergic mice that have impaired Treg-cell generation in response to oral antigen exposure.
LAP
1 T cells are primed for gut homing in skindraining lymph nodes
Tissue homing normally reflects the site of priming, such that T cells primed in skin-draining lymph nodes home back to the skin and T cells primed in the mesenteric lymph nodes (MLNs) home back to the lamina propria. We therefore asked how epicutaneous antigen could induce LAP 1 T cells to appear selectively in the MLN. We first examined kinetics of cell proliferation at different sites. Two days after patch placement, only brachial lymph nodes showed evidence of T-cell proliferation (Fig 5, A) . After 3 days, CFSE-low cells began to appear in inguinal lymph nodes and MLNs and in the small intestinal lamina propria. Mice that had received DO11.10 T cells but did not receive antigen stimulation had a low frequency of CFSE-high cells in the absence of CFSE-low cells at each of the sites examined. To determine whether the appearance of CFSE-low T cells at distal sites was due to migration of cells primed in brachial lymph nodes or due to transport of antigen to distal sites, we treated mice with FTY720, a sphingosine-1-phosphate receptor agonist that prevents exit of T cells from lymph nodes. Cells were recovered 3 days after patch application. The percentage of CFSE-low cells was decreased by FTY720 treatment in inguinal lymph nodes and MLNs and the small intestinal lamina propria (Fig 5, B and C) , whereas the proliferation of cells in the brachial lymph node was unaffected. These data indicate that T cells are primed with antigen within the brachial lymph node and subsequently migrate to gastrointestinal tissues.
We next studied the expression of tissue-homing markers by T cells primed in skin-draining lymph nodes. After epicutaneous OVA exposure, there was a high expression of the skin-homing marker CCR4 22 in all CFSE-low cells and also some induction of the panmucosal homing marker CCR6, 23 whereas the gut-homing marker CCR9 24 was only slightly increased and a4b7 25 was not expressed (Fig 6, A) . In contrast, during oral OVA exposure, proliferating cells in MLN showed high levels of CCR9 and a4b7. Focusing on the expression of tissue-homing markers in different subsets of T cells, we observed that more than 80% of LAP 1
Foxp3
2 T cells expressed CCR9 and more than 50% expressed CCR6 in skin-draining lymph nodes after epicutaneous OVA (Fig 6, B and C) . This was cell-type-specific, as neither Foxp3 1 nor non-Treg cells expressed CCR6 or CCR9 after epicutaneous antigen exposure. LAP 1 cells did not express the gut-homing marker a4b7. All the different subsets of T cells expressed high levels of CCR4, which is in agreement with priming through the skin. These data show that there was a unique imprinting of gut-homing capacity on the LAP 1 Treg-cell subset.
The surface phenotype of LAP 1 cells was more similar to non-Treg cells than to the Foxp3 1 Treg-cell population. There was no expression of conventional Treg-cell markers such as GITR, CD25, and CD103, and lower levels of ICOS than seen in the Foxp3 1 population (Fig 6, D) . 
Clinical protection induced by EPIT occurs through a TGF-b-dependent mechanism
We hypothesized that Treg cells induced during EPIT could be acting directly on allergic effector cells to suppress hypersensitivity reactions during anaphylaxis without affecting T-and B-cell responses. Because TGF-b has been related to the suppression capacity of LAP 1 T cells, mice treated with EPIT were injected with neutralizing anti-TGF-b antibody or isotype control 24 hours before challenge (Fig 7, A) . Acute suppression of TGF-b completely abrogated the protection induced by EPIT (Fig 7, B) . The acute time frame of this neutralization would be too short for modification of B-cell responses, and supports the 1 and LAP 1 T cells generated in MLN (Fig 3, C) and spleen (Fig 3, D) of mice sensitized to OVA by the oral route or the skin route vs naive mice. E, Foxp3 1 and LAP
1
T cells in MLN from naive, OVA-sensitized mice, or peanut-sensitized mice. Data are mean 1 SEM of at least 5 mice/group in 2 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001. mice. D, OVA-specific cells in lamina propria after EPIT. Data are mean 1 SEM of at least 6 mice/group (3 mice/group for lamina propria) in 2 independent experiments. LN, Lymph node; *P < .05, **P < .01, and ***P < .001.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 hypothesis that Treg cells may directly suppress mast cells. To test this hypothesis, OVA-specific DO11.10 LAP 1 Treg cells or nonTreg cells as control were transferred into Balb/c mice that had been passively sensitized with serum containing high levels of OVA-specific IgE. The next day, mice were orally challenged with OVA and the mast cell protease MCPT-7 was measured in sera obtained 30 minutes after challenge (Fig 7, C) . Passively sensitized mice responded to oral OVA challenge with an increase in circulating MCPT-7 (Fig 7, D) . Mice receiving OVA-specific naive Balb/c mice) did not suppress mast cell activation in vivo (data not shown). When mice were injected with anti-TGF-b antibody at the moment of the transfer, the levels of MCPT-7 were partially restored (Fig 7, E) , indicating that the suppression of mast cell activation by Treg cells is dependent, at least in part, on TGF-b. Although LAP 1 Treg cells showed the potential to release IL-10 (see Fig E3, A, in this article's Online Repository at www.jacionline.org), degranulation of bone-marrow-derived mast cells stimulated with IL-10 for 24 hours was in fact enhanced, whereas TGF-b suppressed degranulation (Fig E3,  B) . In summary, we show that antigen-specific LAP 1 Treg cells are induced by EPIT, and can directly suppress mast cell activation and downstream type I hypersensitivity reactions.
DISCUSSION
Oral tolerance is a state of antigen-specific systemic unresponsiveness that is mediated by Treg cells educated in the MLNs by CD103
1 DCs. 26 To restore immune tolerance in food-allergic patients, immunotherapy given through the oral route has emerged as a promising treatment. 4, 5 Although desensitization, defined as protection from reactions while on therapy, has been achieved in most subjects treated with OIT, a lack of permanent tolerance and recurrence of reactions to foods has been found after OIT is discontinued. 4, 6, 8 Our data suggest that an impaired generation of Treg cells in the food-allergic gastrointestinal tract underlies this resistance to oral tolerance induction, and we identify skingut immune communication as a novel means to induce tolerance. Previous studies have documented the efficacy of this approach in suppression of allergic inflammation, [17] [18] [19] [20] [21] and for the first time we demonstrate efficacy in food-induced systemic anaphylaxis.
Allergen-specific immunotherapy has been described as a sequential response, with an early decrease in mast cell and basophil activity associated with a rise in allergen-specific IgG 4 antibodies, and a subsequent generation of allergen-specific Treg cells that is essential for the development of sustained tolerance. Treg-cell development is believed to be necessary to suppress T H 2 responses, and reduce allergen specific IgE and effector cell activation. 27 Our data show that the intestine of food-allergic mice is not capable of supporting Treg-cell generation in response to fed antigens. This is in agreement with recently reported results, 16 and provides an explanation for the lack of sustained efficacy of OIT in the treatment of food allergy in humans 28 and mice. 15 Our data show that this Treg-cell defect is limited to the sensitizing allergen, which may be due to the suppressive effect of mast cell activation on Treg-cell generation. 16 Mast cell degranulation can induce maturation and migration of dendritic cells to lymph nodes 29 and mast cell activators have been shown to function as adjuvants. 30 Our data show that this defect in Tregcell generation was tissue-specific, and the skin could support Treg-cell generation in sensitized mice. This Treg-cell generation in skin was paralleled by a trend of increased efficacy of EPIT compared with OIT in preventing anaphylaxis. Therefore, the site of immunotherapy is a critical factor in clinical efficacy.
Oral tolerance is mediated by antigen-specific Foxp3 1 Treg cells induced in the periphery. 9 T H 3 regulatory cells, characterized by the expression of LAP on their surface, were also originally described as key players in the development of oral tolerance. Feeding of self-antigens including myelin basic protein induces an expansion of T H 3 cells in mice and humans.
11,31 These previously described T H 3 cells are consistent with the phenotype of gastrointestinal T cells induced by epicutaneous antigen exposure in our study. T H 3 cells induced by feeding can suppress experimental models of colitis, systemic lupus erythematosus, multiple sclerosis, and diabetes. [32] [33] [34] [35] [36] Although not specifically termed T H 3 cells, LAP 
Foxp3
2 cells induced by inhaled antigen can suppress allergic eosinophilia in the lung. 37 In humans, T H 3 cells have been found in blood 38 and in tumors, with higher immunosuppressive activity than that of Foxp3 Treg cells by epicutaneous antigen was a novel and unexpected finding. The gastrointestinal tract and skin provide tissuespecific T-cell imprinting, such that T cells home back to the initial site of priming. [46] [47] [48] [49] When we examined antigen-specific proliferating T cells as a whole, these paradigms were true. However, when LAP 1 T cells were examined in skin-draining lymph nodes, CCR9 and CCR6 were highly expressed on LAP 1 T cells together with CCR4, conferring a phenotype capable of homing to multiple tissues including the gastrointestinal tract. This was unique to this population and not observed on Foxp3
1 Treg cells or non-Treg cells. Intranasal vaccination has also been described to elicit migration of antigen-specific T cells to the MLN that can protect against intestinal pathogens, 50,51 indicating that tissuespecific imprinting is a flexible and cell-type-specific process. Understanding how to manipulate this homing potential has major implications for vaccine and immunotherapy design.
The mechanism by which immunotherapy leads to clinical protection has primarily been thought to be due to changes in the antibody repertoire, with sustained protection requiring a loss of allergen specific IgE. However, in human immunotherapy trials, allergen specific IgE and basophil activation have not been able to discriminate between those with transient desensitization versus sustained tolerance. 4, 8 Treg cells are thought to participate in this process by suppressing T H 2 responses necessary for the maintenance of IgE. The suppression of T H 2 responses would also be expected to reduce local tissue inflammation. EPIT has previously been described to suppress airway hyperreactivity and allergic esophago-gastro-enteropathy [17] [18] [19] through the generation of CD25 1 Treg cells. 21 We show that TGF-b is critical for protection against anaphylaxis, but through a novel mechanism involving a direct suppression of mast cell activation by Treg cells rather than through modulation of antibody levels. It has been reported that CD25
1 Treg cells can inhibit mast cell degranulation directly through a contact-dependent manner 52 and that transfer of Treg cells can suppress anaphylaxis. 53 In vitro studies identify the suppressive mechanisms as OX40-OX40L interactions 54 and soluble and surface-bound TGFb. 53, 55, 56 In addition, CD25 1 Treg cells reduce FcεRI surface expression on mast cells, reducing antigen sensitivity. 52 Our in vitro studies support a role for TGF-b, but not IL-10, in suppression of mast cells. However, neutralization experiments in vivo suggest that additional mechanisms beyond TGF-b contribute to mast cell suppression. Although our data focus on LAP 1 Treg cells because of our finding that they are the main Treg cells induced early in EPIT, our data do not rule out a role for Foxp3
1
CD25
1 Treg cells in clinical protection. Neutralization of TGF-b would also be expected to suppress the activity of Foxp3
-induced Treg cells. T H 3 cells promote the development of Foxp3
1 Treg cells 57 and therefore there may be a contribution by both Treg-cell subsets after prolonged immunotherapy.
Our data show for the first time that EPIT generates gut-homing antigen-specific LAP 1 Treg cells that can directly suppress systemic anaphylaxis without upstream modification of humoral or cellular immunity. This changes the paradigm by which Treg cells are thought to contribute to tolerance to allergens. Optimization of antigen delivery and Treg-cell generation by the epicutaneous route may be the most effective means for the generation of a safe and effective treatment for food allergy leading to sustained immune tolerance.
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Key messages
d EPIT protects against food-induced anaphylaxis independent of the initial route of sensitization.
d Treg-cell generation by the oral route is impaired in allergic mice, whereas epicutaneous antigen delivery induces gut-homing LAP 1 Foxp3 2 Treg cells.
d EPIT prevents food-induced anaphylaxis by a TGF-bdependent mechanism.
d Treg cells directly suppress mast cell activation in response to a food challenge. experiments. PMA, Phorbol 12-myristate 13-acetate. *P < .05, ****P < .0001 versus untreated mast cells.
